These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 8170620)

  • 1. Pharmacotherapy of cocaine abuse: preclinical development.
    Witkin JM
    Neurosci Biobehav Rev; 1994; 18(1):121-42. PubMed ID: 8170620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Behavioral effects of cocaine: interactions with D1 dopaminergic antagonists and agonists in mice and squirrel monkeys.
    Katz JL; Kopajtic TA; Myers KA; Mitkus RJ; Chider M
    J Pharmacol Exp Ther; 1999 Oct; 291(1):265-79. PubMed ID: 10490913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of cocaine abuse: pharmacotherapy.
    Kleber HD
    Ciba Found Symp; 1992; 166():195-200; discussion 200-6. PubMed ID: 1638913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Behavioral effects of cocaine and dopaminergic strategies for preclinical medication development.
    Platt DM; Rowlett JK; Spealman RD
    Psychopharmacology (Berl); 2002 Oct; 163(3-4):265-82. PubMed ID: 12373428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Buprenorphine as a pharmacotherapy for cocaine abuse: a review of the evidence.
    Compton PA; Ling W; Charuvastra VC; Wesson DR
    J Addict Dis; 1995; 14(3):97-114. PubMed ID: 8555282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopamine receptor agonists, partial agonists and psychostimulant addiction.
    Pulvirenti L; Koob GF
    Trends Pharmacol Sci; 1994 Oct; 15(10):374-9. PubMed ID: 7809953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Buprenorphine suppresses cocaine self-administration by rhesus monkeys.
    Mello NK; Mendelson JH; Bree MP; Lukas SE
    Science; 1989 Aug; 245(4920):859-62. PubMed ID: 2772637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A review of the effects of dopaminergic agents on humans, animals, and drug-seeking behavior, and its implications for medication development. Focus on GBR 12909.
    Rothman RB; Glowa JR
    Mol Neurobiol; 1995; 11(1-3):1-19. PubMed ID: 8561954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacotherapeutic interventions for cocaine abuse: present practices and future directions.
    Crosby RD; Halikas JA; Carlson G
    J Addict Dis; 1991; 10(4):13-30. PubMed ID: 1685672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ionotropic and metabotropic glutamate receptor structure and pharmacology.
    Kew JN; Kemp JA
    Psychopharmacology (Berl); 2005 Apr; 179(1):4-29. PubMed ID: 15731895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Agonist efficacy, drug dependence, and medications development: preclinical evaluation of opioid, dopaminergic, and GABAA-ergic ligands.
    Bergman J; France CP; Holtzman SG; Katz JL; Koek W; Stephens DN
    Psychopharmacology (Berl); 2000 Dec; 153(1):67-84. PubMed ID: 11255930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serotonin 5-HT2A and 5-HT2C receptors as potential targets for modulation of psychostimulant use and dependence.
    Bubar MJ; Cunningham KA
    Curr Top Med Chem; 2006; 6(18):1971-85. PubMed ID: 17017968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The behavioral pharmacology and therapeutic potential of lorcaserin for substance use disorders.
    Collins GT; Gerak LR; France CP
    Neuropharmacology; 2018 Nov; 142():63-71. PubMed ID: 29246856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospects for serotonin 5-HT2R pharmacotherapy in psychostimulant abuse.
    Bubar MJ; Cunningham KA
    Prog Brain Res; 2008; 172():319-46. PubMed ID: 18772040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of ADCI against convulsant and locomotor stimulant effects of cocaine: comparison with the structural analogs dizocilpine and carbamazepine.
    Seidleck BK; Thurkauf A; Witkin JM
    Pharmacol Biochem Behav; 1994 Apr; 47(4):839-44. PubMed ID: 8029253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sigma-1 receptors: potential targets for the treatment of substance abuse.
    Robson MJ; Noorbakhsh B; Seminerio MJ; Matsumoto RR
    Curr Pharm Des; 2012; 18(7):902-19. PubMed ID: 22288407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medications development at the National Institute on Drug Abuse: focus on cocaine.
    Johnson DN; Vocci FJ
    NIDA Res Monogr; 1993; 135():57-70. PubMed ID: 8289904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and pharmacological evaluation of potent and highly selective D3 receptor ligands: inhibition of cocaine-seeking behavior and the role of dopamine D3/D2 receptors.
    Campiani G; Butini S; Trotta F; Fattorusso C; Catalanotti B; Aiello F; Gemma S; Nacci V; Novellino E; Stark JA; Cagnotto A; Fumagalli E; Carnovali F; Cervo L; Mennini T
    J Med Chem; 2003 Aug; 46(18):3822-39. PubMed ID: 12930145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mixed κ/μ partial opioid agonists as potential treatments for cocaine dependence.
    Bidlack JM
    Adv Pharmacol; 2014; 69():387-418. PubMed ID: 24484983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High affinity dopamine reuptake inhibitors as potential cocaine antagonists: a strategy for drug development.
    Rothman RB
    Life Sci; 1990; 46(20):PL17-21. PubMed ID: 2111866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.